About Us
Providing a “place” for industry-academia collaboration to solve the issues of commercializing regenerative medicine seeds in a one-stop service
National Cancer Center, Teijin, J-TEC, and Mitsui Fudosan are collaborating to build a regenerative medicine platform in the Kashiwa-no-ha area.
The regenerative medicine platform being developed in Kashiwa-no-ha is a collaboration between the National Cancer Center, Teijin Limited, Japan Tissue Engineering Corporation (J-TEC), and Mitsui Fudosan Co. The platform aims to create innovative treatments for cancer and other unmet medical needs.
| 1 | One-stop service: Integrated support for the entire process from research and development to business planning and commercial production. |
|---|---|
| 2 | Industry-University Collaboration: Efficiently and quickly resolve issues by leveraging the strengths of each institution. |
| 3 | CDMO base: Teijin and J-TEC collaborated to establish CDMO (contract drug manufacturing organization) base to support the development of manufacturing methods and production. |
| 4 | Support for Seeds Holders: We support universities and venture companies with technological seeds to promote the commercialization of regenerative medicine products. |
We support strategic development by preparing development and product images from the early stages of research.
Backcasting-type seeds development
Backcasting in drug development is a method of establishing strategies for subsequent research and development by working backward from an ideal product image. In the development of regenerative medicine products, collaboration between researchers and CDMO companies is important. In order to establish a rational approach to commercialization, it is necessary to clarify long-term goals and formulate concrete steps toward achieving them.
Contact Please feel free to contact us.
Contact Us 
Request Info
About
Program
About the Program to Accelerate Regenerative Medicine, Cell Therapy, and Gene Therapy Businesses
The Kashiwa-no-ha Regenerative Medicine Platform's initiatives have been selected for support under the Acceleration Program for Implementation of Regenerative Medicine, Cell Therapy and Gene Therapy by the Japan Agency for Medical Research and Development (AMED), and we are supporting some of the themes of the basic and applied research projects. We have established a support system with an industry-academia collaboration team that can provide the necessary network support for analysis and implementation by clinical development and product development experts.
Backcasting support focusing on clinical and manufacturing development
About
Kashiwa-no-ha
Smart City
What is Kashiwanoha Smart City?
A city that solves problems, creating a "vision of the future of the world.
Kashiwanoha Smart City is promoting urban development to solve problems through a system of public-private-academic collaboration under the three themes of "environmental symbiosis," "health and longevity," and "creation of new industries," and has been selected as an advanced model project for the Smart City Model Project for the realization of "Society 5.0" by the Ministry of Land, Infrastructure, Transport and Tourism. The area has excellent accessibility, being only about 30 minutes from central Tokyo, and is a center of knowledge where Japan's leading research institutions, including the University of Tokyo and Chiba University, are located within a 2-kilometer radius of Kashiwanoha Campus Station.
Teijin and J-TEC, a Teijin Group company engaged in regenerative medicine, are collaborating to build a CDMO center at Mitsui Link Lab Kashiwa-no-ha 1, which is adjacent to the National Cancer Center Hospital East and its Exploratory Oncology Research & Clinical Trial Center and operated by Mitsui Fudosan, to enhance their respective strengths and synergy.
